

Malthus : Prostate Cancer Decision Tree : Updated March 2013

<b>Prostate Cancer</b> Low Risk T1-2a N0 M0 Gleason <7 PSA<10 <b>25%</b>	Fit for radical Treatment 78% <sup>38</sup>	Active surveillance No RT 25% of Low risk	No progression <b>70%</b>						
			Progression <b>30%</b>	Local <b>90-100%</b> <b>95%</b>	Surgery <b>15%</b> <b>ECRIC</b> Brachytherapy <b>13%</b> <b>ECRIC</b> XBRT 74 Gy/ 37*f ] <b>72%</b>				
					Immediate RT 64-66 Gy/32-33f* <b>10% of +ve margin</b> <sup>9,13,16</sup>				
			Surgery <b>20% of low risk</b> <b>No patient over 75</b> <b>No patient under 50</b>	Positive margin <sup>1</sup> <b>10% of surgery</b>	Surveillance <sup>13,16</sup> No Radiotherapy <b>90%</b>	No progression No radiotherapy <b>85%</b>		Salvage RT <sup>1</sup> 64 Gy/32f* RADICALS TRIAL 66 Gy/33f vs. 52.5 Gy/20f <b>50% est Dr K</b>	
						Progression <b>10%</b> <b>15%</b>	Local <b>80-90%</b> <b>85%</b>		Distant <b>10-20%</b> <b>15%</b>
								No recurrence <b>90%</b>	
						Recurrence <b>10%</b>		Local <b>85%</b>	Salvage Radiotherapy <sup>1</sup> 64 Gy/32f* over 6+/52 <b>85%</b>
			Negative margin No radiotherapy <b>90% of surgery</b>		No radiotherapy <b>15%</b>				
			Brachytherapy and External beam radiotherapy EBRT <b>55% of low risk</b>	Brachytherapy <b>10%</b>	No recurrence		No radiotherapy		
					Recurrence	Local recurrence	No RT		
Distant		See M1 tree <b>10-20% of BT low risk patients</b>							
XBRT <b>45%</b>		XBRT RT 74Gy/37f* <sup>18,19,23</sup>							
Unfit for radical Treatment 22% <sup>38</sup>	Watchful waiting No RT <b>10%</b>	No progression <b>70% of watchful waiting</b>							
		Progression <b>30% of watchful waiting</b>	<b>90-100% 90%</b> Local progression. <b>Hormone treatment. 25% of local progression develop mets and follow M1</b>						
			<b>0-10% 10%</b> M1 Hormone treatment. <b>50% develop symptomatic mets see M1 tree</b>						
Intermediate risk T2b-2c, GS 7 PSA 10-20 <b>25%</b>	Fit for radical Treatment 78% <sup>38</sup>	10% Active Surveillance No radiotherapy	No progression <b>70%</b>		No Radiotherapy				
			Progression <b>30%</b>	Local progression <b>80-90%</b> <b>90%</b>	Surgery <b>15%</b>				
					XBRT 74 Gy/37f* 78 Gy/39f <b>72%</b>				
					Brachytherapy <b>13%</b>				
			Distant metastases see M1 tree <b>10%</b>						
			Surgery <b>20%</b>	35% Positive margin <sup>1</sup> Consider RADICALS trial	Surveillance <sup>9,13,16</sup> <b>90%</b>	Immediate adjuvant radiotherapy <sup>9,13,16</sup> 64 Gy/32f* in 6+/52 <b>10%</b>		No recurrence <b>85%</b>	No radiotherapy
						Recurrence <b>15%</b>	Local recurrence, PSA rise ↑ <b>85%</b>		
								Distant <b>15%</b>	

Malthus : Prostate Cancer Decision Tree : Updated March 2013

				No recurrence <b>90%</b>	No radiotherapy		
			<b>65%</b> Negative margin	Recurrence <b>10%</b>	PSA rise ↑, <b>95%</b> Local recurrence	Salvage radiotherapy 64-66 Gy/32-33*f	
					Distant <b>5%</b>	See M1 tree	
		Radiotherapy <b>60-70% 70%</b>	XBRT 74 Gy/37f, 78 Gy/39f* <b>90%</b> of RT. <b>10%</b> will go to M1				
			Brachytherapy <sup>21</sup> <b>10% 20-25# +BT boost NB 10%</b> of this group will go onto M1				
	Unfit for radical Treatment 22% <sup>38</sup>	Watchful waiting No RT <b>10%</b>	No progression <b>70% of watchful waiting</b>				
			Progression <b>30% of watchful waiting</b>	<b>90%</b> Local progression. <b>Hormone treatment.</b> <b>25% of local progression develop mets and follow M1</b>			
High risk T3-T4 GS>7 PSA>20 <b>25%</b>	Fit for radical Treatment 78% <sup>38</sup>	<b>80-90% of high risk patients 80%</b> Hormones <sup>4,10</sup> Radiotherapy <sup>5</sup>	XBRT 80 Gy/40f, 74 Gy/37f <sup>1</sup> 78 Gy/39f <sup>15</sup> . XBRT 19-20f XBRT + Brachytherapy <b>13-16 f</b>				
			Immediate Radiotherapy 64 Gy/32f* <b>Radicals trial 33f vs 20f</b>				
			Surgery Found to be pT3 +ve margins <b>10%</b> <b>Radicals trial 33f vs 20f</b>	Surveillance <sup>2,3</sup>	No recurrence	No RT	
	Recurrence	Local recurrence, Salvage <sup>1</sup> radiotherapy 64 Gy/32f* <b>Radicals trial 33f vs 20f</b>					
					PSA rise ↑		
				Distant See M1 tree			
		Hormones alone <b>10%</b> <b>10-20%</b>	No Radiotherapy <b>80-90%</b>				
			Radiotherapy <b>10-20%</b>	<b>10%</b> receive <b>37-40f</b> * <b>10%</b> receive <b>20f</b> <b>80%</b> receive <b>5-6f</b>			
	Unfit for radical Treatment 22% <sup>38</sup>	Watchful waiting No RT <b>10%</b>	No progression <b>70% of watchful waiting</b>				
			Progression <b>30% of watchful waiting</b>	<b>90%</b> Local progression. <b>Hormone treatment.</b> <b>25% of local progression develop mets and follow M1</b>			
M1 <b>25%</b>	No RT +/-Hormones <b>50%</b>						
	RT +/- Hormones <b>50% of M1</b>	Local <b>10%</b>	Palliative to prostatic tissues-outlet obstruction, 30 Gy/10f, 20 Gy/5f pain, haematuria 8 Gy/1f <b>3-5f</b>				
		Distant <b>90%</b>	Metastases Symptomatic	Bone RT 8 Gy/1f [ <b>50%</b> ] , 20 Gy/5f, <b>[50%]</b> Brain 20 Gy/5f, Good PS 30 Gy/10f Spinal Cord Compression 20/5f			
			Metastases Asymptomatic	No radiotherapy			

Clinical estimates are in red

**References**

1. Andrew J. Stephenson, MD, Shahrokh F. Shariat, MD, Michael J. Zelefsky, MD, Michael W. Kattan, PhD, E. Brian Butler, MD, Bin S. Teh, MD, Eric A. Klein, MD, Patrick A. Kupelian, MD, Claus G. Roehrborn, MD, David A. Pistenmaa, MD, Heather D. Pacholke, MD, Stanley L. Liauw, MD, Matthew S. Katz, MD, Steven A.

- Leibel, MD, Peter T. Scardino, MD, Kevin M. Slawin, MD. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. *JAMA*. 2004;291:1325-1332
2. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *JAMA*. 2006 Nov 15;296(19):2329-35.
  3. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. *J Clin Oncol*. 2009 Jun 20;27(18):2924-30. Epub 2009 May 11.
  4. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. *Lancet*. 2009 Jan 24;373(9660):301-8. Epub 2008 Dec 16.
  5. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? *Int J Radiat Oncol Biol Phys*. 2007 Jul 1;68(3):682-9. Epub 2007 Mar 29.
  6. Kerba M, Miao Q, Zhang-Salomons J, Mackillop W. Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach. *Clin Oncol (R Coll Radiol)*. 2010 Dec;22(10):801-9. Epub 2010 Aug 24.
  7. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. *Int J Radiat Oncol Biol Phys*. 2005 Apr 1;61(5):1285-90.
  8. Foroudi F, Tyldesley S, Barbera L, Huang J, Mackillop WJ. Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2003 Jan 1;55(1):51-63.
  9. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet*. 2005 Aug 13-19;366(9485):572-8.
  10. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. *JAMA*. 2008 Jan 23;299(3):289-95.
  11. Tiffany Daly, Brigid E Hickey, Margot Lehman, Daniel P Francis. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Citation: Daly T, Hickey BE, Lehman M, Francis DP. Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Protocol). *Cochrane Database of Systematic Reviews* 2008, Issue 3. Art. No.: CD007234. DOI: 10.1002/14651858.CD007234. Editorial group: Cochrane Prostatic Diseases and

Urologic Cancers Group. Publication status and date: Edited (no change to conclusions), published in Issue 4, 2008.

12. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol.* 2007 Jun;8(6):475-87.
13. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. *N Engl J Med.* 2009 Jun 11;360(24):2516-27.
14. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. *Int J Radiat Oncol Biol Phys.* 1995 Apr 30;32(1):3-12.
15. Stephanie T.H. Peeters, Wilma D. Heemsbergen, Peter C.M. Koper, Wim L.J. van Putten, Annerie Slot Michel F.H. Dielwart, Johannes M.G. Bonfrer, Luca Incrocci, and Joos V. Lebesque Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy.
16. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. *J Clin Oncol.* 2007 Sep 20;25(27):4178-86.
17. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol.* 2007 May 20;25(15):2035-41.
18. M. Roach III, M. DeSilvio, C. Lawton, V. Uhl, M. Machtay, M.J. Seider, M. Rotman, C. Jones, S.O. Asbell, R.K. Valicenti, S. Han, C.R. Thomas Jr, and W.S. Shipley. Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413. *J Clin Oncol* 21:1904-1911
19. D Dearnaley<sup>1,3</sup>, G Sumo<sup>1</sup>, I Syndikus<sup>2</sup>, V Khoo<sup>3</sup>, H Patterson<sup>4</sup>, C South<sup>3</sup>, P Mayles<sup>2</sup>, H Mayles<sup>2</sup>, A Gao<sup>1</sup>, E Hall<sup>1</sup> on behalf of the CHHiP Trial Management Group. Initial Toxicity Results of the Phase III Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) Trial (ISRCTN97182923)
20. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. *Int J Radiat Oncol Biol Phys.* 2009 Aug 1;74(5):1405-18.
21. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. *Radiother Oncol.* 2007 Aug;84(2):114-20. Epub 2007 May 24.

22. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. *Int J Radiat Oncol Biol Phys*. 2005 Feb 1; 61(2):415-9.
23. RADICALS. Radiotherapy and Androgen Deprivation in Combination After Local Surgery. A randomised controlled trial in prostate cancer. <http://www.radicals-trial.org/>
24. Pdraig Warde, Malcolm Mason, Keyue Ding, Peter Kirkbride, Michael Brundage, Richard Cowan, Mary Gospodarowicz, Karen Sanders, Edmund Kostashuk, Greg Swanson, Jim Barber, Andrea Hiltz, Mahesh K B Parmar, Jinka Sathya, John Anderson, Charles Hayter, John Hetherington, Matthew R Sydes, Wendy Parulekar†, for the NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Published **Online** November 3, 2011 DOI:10.1016/S0140- 6736(11)61095-7
25. Christopher Herbert, F.R.C.R., Mitchell Liu, F.R.C.P.C., Scott Tyldesley, F.R.C.P.C., Christopher Herbert, F.W. James Morris, F.R.C.P.C., Michel Joffres, Ph.D., Mandip Khaira, F.R.C.R., Winkle Kwan, F.R.C.P.C., Vitali Moiseenko, Ph.D., and Thomas Pickles, F.R.C.P.C.\* Biochemical Control with Radiotherapy Improves Overall Survival in Intermediate and High-Risk Prostate Cancer Patients Who Have an Estimated 10-Year Overall Survival of >90%. Article in press. *Int J Radiation Oncol Biol Phys*, Vol. -, No. -, pp. 1e6, 2011 doi: 0360-3016

## **Guidelines**

26. NCCN Guidelines™ Version 1.2011 Updates Prostate Cancer
27. The Royal College of Radiologists. Radiotherapy dose-fractionation. The Royal College of Radiologists, London, 2006. <http://www.rcr.ac.uk/publications>
28. Horwich A, Parker C, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2009 May;20 Suppl 4:76-8.
29. Guidelines on Prostate Cancer. A Heidenreich (chairman), M Bolla, S Joniau, MD Mason, V Matveev, N Mottet, H-P Schmid, TH van der Kwast, T Wiegel, F Zattoni. European Association of Urology 2010.
30. National Institute for Health and Clinical Excellence. Prostate Cancer. Diagnosis and Treatment. Issue date: February 2008.
31. Ontario Cancer Care. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer. SC Morgan, C Walker-Dilks, LJ Eapen, EW Winquist, JL Chin, DA Loblaw et.al. Evidence-based series #3-17. Version 2.2010.
32. Pdraig Warde\*, Malcolm Mason\*, Keyue Ding, Peter Kirkbride, Michael Brundage, Richard Cowan, Mary Gospodarowicz, Karen Sanders, Edmund Kostashuk, Greg Swanson, Jim Barber, Andrea Hiltz, Mahesh K B Parmar, Jinka Sathya, John Anderson, Charles Hayter, John Hetherington, Matthew R Sydes†, Wendy Parulekar†, for the NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Published **Online** November 3, 2011 DOI:10.1016/S0140- 6736(11)61095-7

- 33.** Natural History of Progression After PSA Elevation Following Radical Prostatectomy. Charles R. Pound, MD, Alan W. Partin, MD, PhD, Mario A. Eisenberger, MD, Daniel W. Chan, PhD, Jay D. Pearson, PhD, Patrick C. Walsh, MD. JAMA, May 5, 1999—Vol 281, No. 17 1591
- 34.** Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Follow-up of a Randomized Clinical Trial. Ian M. Thompson THE JOURNAL O Vol. 181, 956-962, March 2009, UROLOGY
- 35.** Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. *int J Radiat Oncol Biol Phys.* 2010 Sep 1;78(1):11-8. Epub 2010 Jan 4.
- 36.** 70 Gy Versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Beckendorf V, Guerif S, Le Pris e E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P. *Int J Radiat Oncol Biol Phys.* 2011 Jul 15;80(4):1056-63. Epub 2010 Dec 14.
- 37.** Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, Yoshida O, Arai Y, Usami M, Kotake T, Tobisu K, Ohashi Y, Sumiyoshi Y, Kakizoe T, Shimazaki J. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. *Urology.* 1999 Aug;54(2):313-8.
- 38.** Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. *J Natl Cancer Inst.* 2001;93:1864-71.